Double-Drug boost aims to make Cancer-Killing cell therapy work better
NCT ID NCT07341191
Summary
This study is testing whether adding two oral medications, sonrotoclax and zanubrutinib, to a standard cell therapy (CAR-T) can improve outcomes for adults with mantle cell lymphoma that has returned or stopped responding to prior treatment. The goal is to see if this drug combination before and after the cell therapy leads to more complete and lasting remissions. About 40 participants who are already planning to receive CAR-T therapy will be enrolled to test this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.